Regulatory T cells are redirected to kill glioblastoma by an EGFRvIII-targeted bispecific antibody.
Regulatory T cells (Tregs) play a central role in in tumor escape from immunosurveillance. We report that a bispecific T-cell engager (BiTE) targeting a mutated form of the epidermal growth factor receptor, i.e., EGFRvIII, potently redirects Tregs to kill glioblastoma through the granzyme-perforin pathway.
Duke Brain Tumor Immunotherapy Program; Division of Neurosurgery; Department of Surgery; Duke University Medical Center; Durham, NC USA.
Bryan D
BD
Choi
Duke Brain Tumor Immunotherapy Program; Division of Neurosurgery; Department of Surgery; Duke University Medical Center; Durham, NC USA.
Patrick C
PC
Gedeon
Duke Brain Tumor Immunotherapy Program; Division of Neurosurgery; Department of Surgery; Duke University Medical Center; Durham, NC USA.
Luis
L
Sanchez-Perez
The Preston Robert Tisch Brain Tumor Center at Duke; Duke University Medical Center; Durham, NC USA.
Darell D
DD
Bigner
Duke Brain Tumor Immunotherapy Program; Division of Neurosurgery; Department of Surgery; Duke University Medical Center; Durham, NC USA ; The Preston Robert Tisch Brain Tumor Center at Duke; Duke University Medical Center; Durham, NC USA.
John H
JH
Sampson
bispecific antibodies; central nervous system neoplasms; epidermal growth factor receptor; glioblastoma; granzymes; regulatory T cells